For Research Use Only — Not for human or veterinary use.

Education

Tesamorelin (TES-10): Growth-Hormone-Releasing Factor Analog in Research Literature

A research overview of the GHRH analog tesamorelin, its receptor-mediated mechanism, and the visceral-fat, hepatic, and cognitive research domains it has been studied in.

TES-10
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), studied for its ability to stimulate endogenous, pulsatile growth hormone release rather than introducing exogenous GH directly.[1]
  • Pooled phase 3 trial data reported significant reductions in visceral adipose tissue (VAT) and waist circumference sustained through 52 weeks of study.[2]
  • A separate randomized trial reported reductions in both visceral fat and liver fat in the same study population.[3]
  • A controlled trial in older adults, including participants with mild cognitive impairment, reported improvements in executive function and short-term verbal memory.[4]
  • The proposed mechanism runs through GH-stimulated hepatic IGF-1 production, with downstream effects studied separately in adipose, hepatic, and cognitive research models.[1]

What It Is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that triggers the pituitary gland to release growth hormone (GH). Unlike compounds that introduce GH directly, tesamorelin research is built around stimulating the body's own pulsatile GH release pattern, which is studied as a way of preserving normal feedback regulation compared to exogenous GH administration.[1]

Mechanism & Pathway

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, stimulating GH release. The released GH subsequently stimulates hepatic production of insulin-like growth factor-1 (IGF-1), and clinical trial data report tesamorelin increasing IGF-1 levels from baseline in a dose-dependent manner.[1] Downstream, GH is studied for promoting lipolysis via hormone-sensitive lipase activation in adipocytes, with visceral fat cells reported as particularly responsive due to higher beta-adrenergic receptor density — this is the proposed basis for the visceral-fat-specific effects reported in trial data.[2] Separately, a cognitive research trial reported that tesamorelin-driven IGF-1 elevation was associated with changes in brain GABA and other neurometabolite levels, alongside improved executive-function test scores.[4]

Research Domains

  • Visceral adipose tissue research — pooled phase 3 trial data reported significant, sustained reductions in visceral adipose tissue and waist circumference through 52 weeks.[2]
  • Hepatic fat research — a randomized clinical trial reported reductions in liver fat content alongside visceral fat in the same study population.[3]
  • Cognitive research — a controlled trial in healthy older adults and adults with mild cognitive impairment reported improved executive function and short-term verbal memory following 20 weeks of treatment.[4]
  • Pharmacological review literature — review articles summarize tesamorelin's receptor pharmacology and study history as a GHRH analog.[1]

Comparative Notes

Tesamorelin is mechanistically distinct from the receptor-agonist metabolic peptides elsewhere in this catalog, such as R3 (retatrutide), which acts directly on GLP-1, GIP, and glucagon receptors. Tesamorelin instead acts upstream, at the GHRH receptor, stimulating endogenous GH release rather than engaging metabolic receptors directly — a mechanistically separate research pathway toward body-composition-related endpoints.

TES-10 product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for a TES-10 research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Spooner LM, Olin JL (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. PMID: 22298602
  2. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. PMID: 20554713
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. PMID: 25038357
  4. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. PMID: 22869065

FAQ

Tesamorelin is a GHRH analog that binds the GHRH receptor to stimulate endogenous, pulsatile growth hormone release, which in turn stimulates hepatic IGF-1 production.[1]

Visceral adipose tissue reduction is the most extensively studied domain, with pooled phase 3 trial data reporting sustained reductions through 52 weeks.[2]

Yes. A separate controlled trial studied tesamorelin in cognitive research contexts, reporting improved executive function and short-term verbal memory in older adults.[4]

The two act on different pathways: TES-10 stimulates endogenous growth hormone release via the GHRH receptor, while R3 (retatrutide) acts directly on GLP-1, GIP, and glucagon receptors.

A COA for a TES-10 research vial should report confirmed amino acid sequence and net peptide content, consistent with the documentation standard used across this catalog.

No. TES-10 is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance outside their own regulated trial protocols.

Related Guides